

## **FDA Declines Application for Ampligen**

Written by Administrator

Thursday, 07 February 2013 00:00 - Last Updated Thursday, 07 February 2013 07:29

---

### **Hemispherx Biopharma Receives Complete Response Letter From FDA on Ampligen(R) New Drug Application for Chronic Fatigue Syndrome**

**PHILADELPHIA, Feb. 4, 2013 (GLOBE NEWSWIRE) --**

**Hemispherx Biopharma, Inc.**

**(NYSE MKT:HEB) (the "Company" or "Hemispherx"), announced that it received a Complete Response Letter from the US Food and Drug Administration ("FDA") declining to approve its new drug application ("NDA") for Ampligen®**

**for Chronic Fatigue Syndrome ("CFS"). The FDA said Hemispherx should conduct at least one additional**

## FDA Declines Application for Ampligen

Written by Administrator

Thursday, 07 February 2013 00:00 - Last Updated Thursday, 07 February 2013 07:29

---

**clinical trial, complete various nonclinical studies and perform a number of data analyses.**

[...more](#)